PrEP-001

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Viral Upper Respiratory Tract Infection

Conditions

Viral Upper Respiratory Tract Infection

Trial Timeline

Apr 6, 2016 → Sep 30, 2016

About PrEP-001

PrEP-001 is a phase 2 stage product being developed by hVIVO for Viral Upper Respiratory Tract Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT03338556. Target conditions include Viral Upper Respiratory Tract Infection.

What happened to similar drugs?

1 of 6 similar drugs in Viral Upper Respiratory Tract Infection were approved

Approved (1) Terminated (1) Active (4)
🔄Tozorakimab + PlaceboAstraZenecaPhase 3
🔄V503 + GARDASILMerckPhase 3
🔄Tobevibart + ElebsiranVir BiotechnologyPhase 3
🔄Tobevibart + Elebsiran + BulevirtideVir BiotechnologyPhase 3
Azithromycin plus hydroxychloroquineIterum TherapeuticsPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT03338556Phase 2Completed
NCT03220048Phase 2Completed